Maricrio

Omeprazole, the active ingredient in Maricrio, is a proton pump inhibitor presented as a standard strength tablet for oral use. It reduces gastric acid secretion and is employed to treat gastro‑oesophageal reflux disease, peptic ulcer disease, erosive esophagitis and as part of Helicobacter pylori eradication regimens in adult patients.

GNH USA supplies Maricrio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Omeprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal conditions.

Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and promoting healing of the esophageal lining. Peptic ulcer disease: suppresses gastric acid to allow ulcer healing and prevent recurrence. Erosive esophagitis: decreases acid‑induced inflammation, facilitating mucosal repair. Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic combinations by maintaining a less acidic gastric environment.

Omeprazole may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of stomach discomfort or urge to vomit. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Bone fracture: increased risk of hip, wrist or spine fractures with long‑term use. - Hypomagnesemia: low serum magnesium causing muscle weakness or cardiac arrhythmia. - Severe allergic reaction: rash, swelling, or anaphylaxis requiring immediate medical attention.

When prescribing or dispensing omeprazole, several precautions should be observed to ensure safe use.

- Assess renal and hepatic function: dose adjustment may be needed in severe impairment. - Long‑term therapy monitoring: evaluate need for continued treatment to avoid unnecessary exposure. - Drug interaction review: check concomitant medications that may affect acid levels or omeprazole metabolism. - Pregnancy and lactation counseling: discuss potential risks and benefits with the patient. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Omeprazole can alter the pharmacokinetics of several medicines; interactions are categorized by clinical significance.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir or other protease inhibitors: markedly decreased absorption, compromising antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Diazepam: increased plasma levels, observe for enhanced sedation. - Methotrexate (high dose): reduced renal clearance, watch for toxicity.